Massimo Massaia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2404585/publications.pdf

Version: 2024-02-01

189	6,767	53794	69250
papers	citations	45 h-index	77 g-index

190	190	190	8274
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
2	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients. Blood Cancer Journal, 2022, 12, 8.	6.2	5
3	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, , 1-4.	1.3	3
4	Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases. Clinical Case Reports (discontinued), 2021, 9, 1066-1071.	0.5	1
5	Molecular dynamics of targeting CD38 in multiple myeloma. British Journal of Haematology, 2021, 193, 581-591.	2.5	16
6	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
7	Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment. Medicina (Lithuania), 2021, 57, 1104.	2.0	3
8	CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. Scientific Reports, 2021, 11, 21230.	3.3	8
9	The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report. Blood, 2021, 138, 4684-4684.	1.4	3
10	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. Bone Marrow Transplantation, 2021, , .	2.4	0
11	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. Seminars in Cell and Developmental Biology, 2020, 98, 80-89.	5.0	14
12	HIF-1Î± is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica, 2020, 105, 1042-1054.	3.5	39
13	Anticancer innovative therapy: Highlights from the ninth annual meeting. Cytokine and Growth Factor Reviews, 2020, 51, 1-9.	7.2	0
14	Immunomodulatory and clinical effects of daratumumab in Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 191, e28-e32.	2.5	13
15	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
16	Immunoglobulin M (IgM) multiple myeloma versus WaldenstrÃ¶m macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. Journal of Medical Case Reports, 2020, 14, 75.	0.8	6
17	Metabolic approaches to rescue antitumor V gamma 9V delta 2 T-cell functions in myeloma. Frontiers in Bioscience - Landmark, 2020, 25, 69-105.	3.0	4
18	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. Blood, 2020, 136, 47-49.	1.4	1

#	Article	IF	Citations
19	A Position Paper on IgM-Enriched Intravenous Immunoglobulin Adjunctive Therapy in Severe Acute Bacterial Infections: The TO-PIRO SCORE Proposal. New Microbiologica, 2019, 42, 176-180.	0.1	3
20	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	1.7	55
21	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD⁺. OncoImmunology, 2018, 7, e1458809.	4.6	59
22	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term followâ€up. British Journal of Haematology, 2018, 181, 693-695.	2.5	1
23	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. OncoImmunology, 2018, 7, e1341032.	4.6	11
24	Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. Frontiers in Oncology, 2018, 8, 508.	2.8	15
25	Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 286.	8.6	32
26	Regulation of HIF-1 α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S214.	0.4	0
27	ABCA1, apoA-I, and BTN3A1: A Legitimate MÃ©nage Ã Trois in Dendritic Cells. Frontiers in Immunology, 2018, 9, 1246.	4.8	16
28	Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. Frontiers in Immunology, 2018, 9, 1492.	4.8	21
29	Abstract 2122: Induction of structural and functional effects of myeloma cells after daratumumab treatment. , 2018, , .		1
30	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. Haematologica, 2017, 102, e352-e355.	3.5	9
31	A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). Hematological Oncology, 2017, 35, 426-427.	1.7	0
32	The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells. Nature Communications, 2017, 8, 15663.	12.8	57
33	A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility. Diagnostics, 2017, 7, 57.	2.6	11
34	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget, 2017, 8, 3274-3288.	1.8	13
35	The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S42.	0.4	0
36	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.3	7

#	Article	IF	Citations
37	Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients. Blood, 2016, 128, 2059-2059.	1.4	1
38	A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies. Blood, 2016, 128, 2183-2183.	1.4	1
39	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	1.4	0
40	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. Blood, 2016, 128, 3469-3469.	1.4	0
41	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and VÎ³9VÎ´2 T-Cell Activation By Dendritic Cells. Blood, 2016, 128, 3709-3709.	1.4	0
42	HIF-1Î± Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	1.4	0
43	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	1.4	197
44	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. Haematologica, 2015, 100, e501-e504.	3.5	22
45	Anergic bone marrow VÎ³9VÎ´2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. OncoImmunology, 2015, 4, e1047580.	4.6	58
46	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget, 2015, 6, 29833-29846.	1.8	33
47	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Blood, 2015, 126, 2925-2925.	1.4	0
48	A randomized, openâ€label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2014, 167, 466-477.	2.5	30
49	Chlorambucil plus rituximab with or without maintenance rituximab as firstâ€line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology, 2014, 89, 480-486.	4.1	104
50	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. Haematologica, 2014, 99, e159-e161.	3.5	4
51	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status. Haematologica, 2014, 99, 1605-1610.	3.5	27
52	The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. Blood, 2014, 124, 833-833.	1.4	0
53	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	1.4	0
54	Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells. OncoImmunology, 2013, 2, e25770.	4.6	20

#	Article	IF	Citations
55	Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. Molecular Medicine, 2013, 19, 99-108.	4.4	58
56	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2013, 122, 4177-4177.	1.4	2
57	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. PLoS ONE, 2013, 8, e60975.	2.5	49
58	Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. Giornale Italiano Di Dermatologia E Venereologia, 2013, 148, 453-63.	0.8	4
59	Aminobisphosphonates, statins and the mevalonate pathway: a cross-road to fine-tune the activation of NK and VÎ³9VÎ´2 T cells. IBMS BoneKEy, 2012, 9, .	0.0	3
60	Dysfunctional VÎ³9VÎ´2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood, 2012, 120, 3271-3279.	1.4	51
61	Human Î³Î´ <scp>T</scp>â€cell responses in infection and immunotherapy: Common mechanisms, common mediators?. European Journal of Immunology, 2012, 42, 1668-1676.	2.9	53
62	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology, 2012, 91, 875-888.	1.8	28
63	Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2898-2898.	1.4	0
64	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 3881-3881.	1.4	0
65	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). Blood, 2012, 120, 3878-3878.	1.4	0
66	2.28 Identification by Serological Proteome Analysis (SERPA) of Novel Tumor Associated Antigens in Chronic Lymphocytic Leukemia (CLL). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S176-S177.	0.4	0
67	2.37 Accelerated Activity of the Mevalonate Pathway Supports the Immune Escape and Multidrug-Resistance Phenotype of IGHV Unmutated Chronic Lymphocytic Leukemia Cells. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S182.	0.4	0
68	5.9 Bendamustine and Alemtuzumab Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia: Interim Report of the Italian Trial. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S247-S248.	0.4	0
69	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia, 2011, 25, 828-837.	7.2	61
70	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood, 2011, 117, 6721-6727.	1.4	113
71	VÎ³9VÎ´2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cellular and Molecular Life Sciences, 2011, 68, 2419-2432.	5.4	35
72	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between VÎ³9VÎ´2 T Cells, Î±Î² CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. Journal of Immunology, 2011, 187, 1578-1590.	0.8	77

#	Article	IF	Citations
73	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. Blood, 2011, 118, 294-294.	1.4	6
74	A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.. Journal of Clinical Oncology, 2011, 29, 6629-6629.	1.6	2
75	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. Blood, 2011, 118, 2845-2845.	1.4	0
76	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. Blood, 2011, 118, 735-735.	1.4	0
77	Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy. Current Pharmaceutical Design, 2010, 16, 3007-3014.	1.9	35
78	Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood, 2010, 115, 1873-1879.	1.4	87
79	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. Intensive Care Medicine, 2010, 36, 1666-1674.	8.2	152
80	Zoledronic acid repolarizes tumourâ€associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 2010, 14, 2803-2815.	3.6	228
81	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). Blood, 2010, 116, 1371-1371.	1.4	2
82	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. Blood, 2010, 116, 2462-2462.	1.4	17
83	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	1.4	2
84	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 917-917.	1.4	0
85	Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2010, 116, 1254-1254.	1.4	5
86	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. Blood, 2010, 116, 3602-3602.	1.4	0
87	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. Blood, 2010, 116, 2431-2431.	1.4	0
88	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. Experimental Hematology, 2009, 37, 728-738.	0.4	10
89	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia, 2009, 23, 1062-1072.	7.2	97
90	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. Blood, 2009, 114, 2333-2333.	1.4	12

#	Article	IF	Citations
91	Defective interleukin-2 induction of lymphokine-activatedkiller (LAK) activity in peripheral blood T lymphocytesof patients with monoclonal gammopathies. Clinical and Experimental Immunology, 2008, 79, 100-104.	2.6	23
92	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111, 2765-2775.	1.4	239
93	Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. Blood, 2008, 112, 3167-3167.	1.4	2
94	Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richterâ€™s Syndrome Transformation in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1052-1052.	1.4	0
95	Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma. Clinical Cancer Research, 2007, 13, 5348-5354.	7.0	26
96	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. New England Journal of Medicine, 2007, 356, 1110-1120.	27.0	479
97	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25â˜ into CD25+ T regulatory cells. Blood, 2007, 109, 2871-2877.	1.4	357
98	Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood, 2007, 110, 921-927.	1.4	98
99	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia, 2007, 21, 353-355.	7.2	99
100	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patientâ€specific tumour idiotype protein or idiotype (VDJ)â€derived class Iâ€restricted peptides. British Journal of Haematology, 2007, 139, 415-424.	2.5	58
101	Quantitative Molecular Expression of the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia Cells as a Possible Marker for Minimal Residual Disease Detection.. Blood, 2007, 110, 4229-4229.	1.4	0
102	Intermediate-Dose Melphalan (100 mg/m2)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 475-477.	1.4	22
103	Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. European Journal of Haematology, 2006, 76, 342-347.	2.2	29
104	Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase.. Blood, 2006, 108, 1899-1899.	1.4	0
105	Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica, 2006, 91, 941-8.	3.5	19
106	Effector Î³Î´ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia, 2005, 19, 664-670.	7.2	119
107	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T?cells. European Journal of Immunology, 2005, 35, 1155-1163.	2.9	45
108	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thrombosis and Haemostasis, 2004, 92, 1438-1445.	3.4	61

#	Article	IF	Citations
109	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 2004, 18, 139-145.	7.2	63
110	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200â€‰mg/m2). Leukemia, 2004, 18, 133-138.	7.2	30
111	New drugs for treatment of multiple myeloma. Lancet Oncology, The, 2004, 5, 430-442.	10.7	59
112	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood, 2004, 104, 3052-3057.	1.4	305
113	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica, 2004, 89, 717-41.	3.5	48
114	Behavioral disturbances in the Alzheimer's care units: A six-months observation. Archives of Gerontology and Geriatrics, 2001, 33, 245-252.	3.0	2
115	Risk factors for dementia of Alzheimer's type: A case-control, retrospective evaluation. Archives of Gerontology and Geriatrics, 2001, 33, 253-259.	3.0	7
116	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology, 2001, 113, 1051-1059.	2.5	48
117	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. British Journal of Haematology, 2000, 109, 46-53.	2.5	16
118	Idiotype Vaccination of Myeloma Patients After Chemotherapy. Acta OncolÃ³gica, 2000, 39, 807-808.	1.8	3
119	Antitumor vaccination: where we stand. Haematologica, 2000, 85, 1172-206.	3.5	53
120	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	127
121	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	1.4	2
122	Idiotypic vaccination as therapy for multiple myeloma. Seminars in Hematology, 1999, 36, 34-7.	3.4	7
123	CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. Journal of Immunology, 1999, 162, 6238-46.	0.8	4
124	Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood, 1999, 94, 673-83.	1.4	36
125	Idiotypic vaccination in B-cell malignancies. Trends in Molecular Medicine, 1997, 3, 435-441.	2.6	12
126	DISTRIBUTION OF Tâ€CELL SIGNALLING MOLECULES IN HUMAN MYELOMA. British Journal of Haematology, 1997, 97, 810-814.	2.5	100

#	Article	IF	Citations
127	Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. Blood, 1997, 89, 212-8.	1.4	11
128	Clinical and Immunological Studies in Advanced Cancer Patients Sequentially Treated with Anti CD3 Monoclonal Antibody (OKT3) and Interleukin-2. Leukemia and Lymphoma, 1996, 21, 325-330.	1.3	7
129	Selective induction of CD73 expression in human lymphocytes by CD38 ligation: a novel pathway linking signal transducers with ecto-enzyme activities. Journal of Immunology, 1996, 157, 4354-62.	0.8	25
130	CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+cells. British Journal of Haematology, 1995, 90, 625-632.	2.5	9
131	Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood, 1995, 85, 3679-3687.	1.4	66
132	Reversible Bronchial Hyperresponsiveness Induced by OK-T3/IL-2 Administration in a Patient with Multiple Myeloma. Respiration, 1995, 62, 228-231.	2.6	0
133	T Cells in Multiple Myeloma: Is This a Reliable Population to Count on as Antitumor Effector Cells?. Leukemia and Lymphoma, 1995, 17, 63-70.	1.3	6
134	Usefulness of frequency analysis of cytotoxic T-lymphocytes precursors (CTL-p) for selection of HLA matched unrelated marrow donors. Panminerva Medica, 1995, 37, 168-70.	0.8	1
135	Correlation between disease activity and T-cell CD3 chain expression in a B-cell lymphoma. British Journal of Haematology, 1994, 88, 886-888.	2.5	33
136	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. British Journal of Haematology, 1994, 87, 494-502.	2.5	5
137	Serum levels of tumour necrosis factor-Î± in patients with B-cell chronic lymphocytic leukaemia. European Journal of Cancer, 1994, 30, 1259-1263.	2.8	43
138	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood, 1993, 82, 1787-1797.	1.4	35
139	Cyclosporin A and dipyridamole: An effective combination against the generationa of cytotoxic T lymphocytes (CTL). Pharmacological Research, 1992, 26, 12-13.	7.1	0
140	Constitutive production of tumor necrosis factor-alpha in hairy cell leukemia: possible role in the pathogenesis of the cytopenia(s) and effect of treatment with interferon-alpha.. Journal of Clinical Oncology, 1992, 10, 954-959.	1.6	29
141	Sequential administration of OKT3 (antiâ€CD3) and interleukinâ€2 in two patients with chemoresistant hematological disease. European Journal of Haematology, 1992, 49, 150-152.	2.2	3
142	Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex [see comments]. Blood, 1991, 78, 1770-1780.	1.4	43
143	Difference in Polyamine Transport in Human B and T Lymphocytes. Biological Chemistry Hoppe-Seyler, 1991, 372, 75-78.	1.4	3
144	Dipyridamole in vitro suppresses the generation of Tâ€cell cytotoxic functions: Synergistic activity with cyclosporine. European Journal of Haematology, 1991, 46, 6-10.	2.2	2

#	Article	IF	Citations
145	Amplification of T Cell Activation Induced by CD73 (Ecto-5â€²Nucleotidase) Engagement. Advances in Experimental Medicine and Biology, 1991, 309B, 155-158.	1.6	6
146	Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass. Haematologica, 1991, 76, 383-8.	3.5	4
147	Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositolâ€anchored lymphocyte differentiation antigen ectoâ€5â€²â€nucleotidase (CD73).. Tissue Antigens, 1990, 35, 9-19.	1.0	120
148	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood, 1990, 76, 393-400.	1.4	119
149	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood, 1990, 76, 393-400.	1.4	124
150	Human T cell activation. Synergy between CD73 (ecto-5'-nucleotidase) and signals delivered through CD3 and CD2 molecules. Journal of Immunology, 1990, 145, 1664-74.	0.8	51
151	Multiple myeloma: altered CD4/CD8 ratio in bone marrow. Haematologica, 1990, 75, 129-31.	3.5	8
152	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood, 1990, 76, 393-400.	1.4	40
153	Multiple Myeloma: Beta-2-Microglobulin is not a Useful Follow-Up Parameter. Acta Haematologica, 1989, 82, 122-125.	1.4	18
154	Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma. Tumori, 1989, 75, 1-3.	1.1	4
155	Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.. Journal of Clinical Oncology, 1989, 7, 119-125.	1.6	72
156	CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. European Journal of Immunology, 1989, 19, 1037-1044.	2.9	46
157	B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. Journal of Clinical Immunology, 1989, 9, 329-337.	3.8	4
158	Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. European Journal of Haematology, 1989, 43, 30-34.	2.2	2
159	The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood, 1989, 73, 1020-1027.	1.4	54
160	Altered expression of growth-regulated protooncogenes in human malignant plasma cells. Cancer Research, 1989, 49, 4701-4.	0.9	14
161	Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. Tumori, 1989, 75, 1-3.	1.1	0
162	The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. Blood, 1989, 73, 1020-7.	1.4	12

#	Article	IF	Citations
163	Immune dysregulation in monoclonal gammopathies. Bone Marrow Transplantation, 1989, 4 Suppl 1, 165-7.	2.4	0
164	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	1.4	48
165	Human myeloma: Several subsets of circulating lymphocytes express plasma cellâ€associated antigens. European Journal of Haematology, 1988, 40, 299-304.	2.2	28
166	Biochemical and immunologic abnormalities in peripheral blood T lymphocytes of patients with hemophilia A. European Journal of Haematology, 1988, 41, 334-340.	2.2	5
167	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-1068.	1.4	44
168	Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clinical and Experimental Immunology, 1988, 73, 214-8.	2.6	30
169	The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5'nucleotidase activity. Journal of Immunology, 1988, 141, 3768-75.	0.8	15
170	Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5'nucleotidase deficiency. Journal of Clinical & Laboratory Immunology, 1988, 26, 89-95.	0.1	5
171	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood, 1988, 72, 1064-8.	1.4	8
172	Cytobiological Studies in Multiple Myeloma. Acta Haematologica, 1987, 78, 41-42.	1.4	2
173	Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies. Acta Haematologica, 1987, 78, 239-242.	1.4	17
174	Immunologic and virologic findings in hemophiliacs do not correlate with ectoâ€5â€²nucleotidase activity of peripheral blood lymphocytes. A difference with homosexual men. European Journal of Haematology, 1987, 38, 310-314.	2.2	2
175	Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. Clinical and Experimental Immunology, 1987, 69, 426-32.	2.6	14
176	Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. Alabama Journal of Medical Sciences, 1987, 24, 400-4.	0.1	1
177	Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. Haematologica, 1987, 72, 171-5.	3.5	13
178	Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2+/T8+ lymphocytes. Journal of Immunology, 1986, 137, 484-9.	0.8	21
179	Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. Blood, 1985, 65, 530-534.	1.4	11
180	Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. Blood, 1985, 65, 530-4.	1.4	3

#	Article	IF	Citations
181	Soluble factor(s) released by Concanavalin A activated lymph node lymphocytes induce proliferation and maturation of chronic lymphocytic leukaemia (CLL) B lymphocytes. Journal of Clinical & Laboratory Immunology, 1984, 13, 85-8.	0.1	1
182	Kinetics of circulating B lymphocytes in human myeloma. Blood, 1983, 61, 812-814.	1.4	35
183	Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and postâ€thymic T cells. British Journal of Haematology, 1983, 54, 451-457.	2.5	5
184	Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. British Journal of Haematology, 1983, 54, 451-457.	2.5	16
185	The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. Clinical and Experimental Immunology, 1983, 51, 173-7.	2.6	23
186	Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA). Journal of Clinical & Laboratory Immunology, 1983, 12, 57-61.	0.1	1
187	5â€²nucleotidase, adenosine deaminase and purine nucleoside phosphorylase activities in acute leukaemia. Leukemia Research, 1982, 6, 475-482.	0.8	38
188	Enzymes of purine metabolism in human peripheral lymphocyte subpopulations. Clinical and Experimental Immunology, 1982, 50, 148-54.	2.6	44
189	Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes. Journal of Immunology, 1982, 129, 1430-5.	0.8	75